Abstract: The subject matter of this specification can be embodied in, among other things, a garment that includes a body having a first end and a second end opposite the first end. The body has an anterior knit region having a first knitting pattern configured to stretch across a portion of a wearer's abdominal area, a second knitting pattern configured to stretch across a portion of a wearer's chest area, a posterior knit region having the first knitting pattern configured to stretch about a portion of the wearer's back, a first lateral knit region having a third knitting pattern different from the first knitting pattern configured to stretch about a portion of the wearer's left lateral area, and a second lateral knit region having the third knitting pattern configured to stretch about a portion of the wearer's right lateral area.

Abstract: The subject matter of this specification can be embodied in, among other things, a garment that includes a body having a first end and a second end opposite the first end. The body has an anterior knit region having a first knitting pattern configured to stretch across a portion of a wearer's abdominal area, a second knitting pattern configured to stretch across a portion of a wearer's chest area, a posterior knit region having the first knitting pattern configured to stretch about a portion of the wearer's back, a first lateral knit region having a third knitting pattern different from the first knitting pattern configured to stretch about a portion of the wearer's left lateral area, and a second lateral knit region having the third knitting pattern configured to stretch about a portion of the wearer's right lateral area.

Abstract: The subject matter of this specification can be embodied in, among other things, a garment that includes a body having a first end and a second end opposite the first end. The body has an anterior knit region having a first knitting pattern configured to stretch across a portion of a wearer's abdominal area, a second knitting pattern configured to stretch across a portion of a wearer's chest area, a posterior knit region having the first knitting pattern configured to stretch about a portion of the wearer's back, a first lateral knit region having a third knitting pattern different from the first knitting pattern configured to stretch about a portion of the wearer's left lateral area, and a second lateral knit region having the third knitting pattern configured to stretch about a portion of the wearer's right lateral area.

Abstract: The subject matter of this specification can be embodied in, among other things, a garment that includes a body having a first end and a second end opposite the first end. The body has an anterior knit region having a first knitting pattern configured to stretch across a portion of a wearer's abdominal area, a second knitting pattern configured to stretch across a portion of a wearer's chest area, a posterior knit region having the first knitting pattern configured to stretch about a portion of the wearer's back, a first lateral knit region having a third knitting pattern different from the first knitting pattern configured to stretch about a portion of the wearer's left lateral area, and a second lateral knit region having the third knitting pattern configured to stretch about a portion of the wearer's right lateral area.

Abstract: An upper torso garment and a lower torso garment each comprising a respective torso encircling band. The band includes an inner layer and an outer layer with each layer having a first series of courses. The first series of courses defined by a first, covered elastomeric, yarn and a second, low friction, yarn. The first and second yarns are knit such that the second yarn is float platted with the first yarn.

Abstract: An upper torso garment and a lower torso garment each comprising a respective torso encircling band. The band includes an inner layer and an outer layer with each layer having a first series of courses. The first series of courses defined by a first, covered elastomeric, yarn and a second, low friction, yarn. The first and second yarns are knit such that the second yarn is float platted with the first yarn.

Abstract: Formula (1), X1 represents O or NR6, X2 represents O or NR6, X3 represents O or NR1, R1 represents H or C1 to C3 alkyl, R2 represents H, or linear or branched C1-C8 alkyl optionally including one or more heteroatoms, cyclopropyl, cyclobutyl, cyclohexyl or oxetanyl or amino acid side chain or protected amino acid side chain, or R1 and R2 may form together a saturated, partly saturated or unsaturated 5 or 6 membered ring system, optionally substituted, R3 represents H, cyclopentyl, cyclohexyl, aryl or hydroxyaryl, aryl or hydroxyaryl being optionally substituted by fluorine, or linear or branched C1 to C8 alkyl optionally including a hetero atom, R4 represents phenyl or 5- or 6-membered heterocycles including one or more nitrogen or oxygen atoms optionally substituted with 1 to 4, respectively 5 fluorine atoms, and R6 represents H, or linear or branched alkyl chain having 1 to 3 carbon atoms.

Abstract: Epothilone derivatives of Formula (I) and their use as a pharmaceutical.

Abstract: Epothilone derivatives of Formula (I) and their use as a pharmaceutical.

Abstract: The invention relates to analogues of epothilones, uses and methods of making the same.

Abstract: This invention provides liposomal compositions comprising an epothilone.

Abstract: Epothilone derivatives of Formula (I) and their use as a pharmaceutical.

Abstract: The invention relates to cis- and trans-12, 13-cyclopropyl and 12,13-cyclobutyl epothilones of formula I to IV wherein Ar is a radical represented by the following structure: and the other radicals and symbols have the meanings as defined herein; to their chemical synthesis and biological evaluation; their use in the treatment of neoplastic diseases and to pharmaceutical preparations containing such compounds. The compounds described herein are potent tubulin polymerization promoters and cytotoxic agents.

Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y?SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each, other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R2 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y=SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

Abstract: The invention relates to an oligonucleotide derivative which comprises at least one nucleoside building block of the formula (I) The invention furthermore relates to nucleoside building blocks, intermediates and processes for preparing the oligonucleotide derivatives and the nucleoside building blocks. The invention also relates to pharmaceutical compositions and to uses of the oligonucleotide derivatives and the nucleoside building blocks.

Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that R2 cannot represent 2-phthalimidyl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

Abstract: The present invention provides pharmaceutical liposomal compositions comprising epothilones.

Abstract: A hybrid brassiere is provided. The brassiere has a brassiere body having a pair of side wings/back panels made of circular knit fabric and an integrally knitted band. The brassiere also has a pair of breast cups made from one or more fabrics, namely woven, non-woven, warp knitted, and weft knitted fabrics, and an attachment for connecting the pair of breast cups to the brassiere body.

Abstract: 1